Skip to content

Oral Dynamic Propulsion Appliance in Treatment of Patients With Obstructive Sleeping Apnea

Treatment Effects of Oral Dynamic Propulsion Appliance During the Sleeping Phase in Patients With Obstructive Sleeping Apnea

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07414420
Enrollment
40
Registered
2026-02-17
Start date
2026-03-01
Completion date
2027-09-01
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea (OSA)

Keywords

obstructive sleep apnea, oral apparatus

Brief summary

Obstructive Sleep Apnea (OSA) is one of the most prevalent sleep disorders, affecting nearly one billion people worldwide. It is characterized by repeated episodes of complete (apnea) or partial (hypopnea) obstruction of the upper airway during sleep, leading to snoring, excessive daytime sleepiness, insomnia, morning headaches, nocturia, behavioral changes, reduced concentration, and serious cardiovascular and metabolic complications such as insulin resistance, type II diabetes, and metabolic syndrome. During the night, patients may experience up to a hundred apnea or hypopnea events lasting from 10 to 120 seconds. Therapy for OSA depends on its severity, defined by five or more obstructive events per hour of sleep. Over the past decade and a half, oral appliances (OAs) have become the treatment of choice for mild to moderate forms of OSA due to their efficacy and comfort. For this purpose, the DYNAMIC PROPULSION ORAL APPLIANCE (DPOA) has been designed with a mechanism that provides controlled, gentle, gradual and automatic mandible movement in propulsion during sleep. Unlike conventional OAs that fix the mandible in only one propulsive position, causing stress to orofacial complex and upper airway structures such as masticatory muscles and the temporomandibular joints, the DPOA provides gradual, automatic mandibular movement to the previously determined propulsive position. This gradual adaptation minimizes stress, reduces side effects, and enhances treatment success. In that way, the DPOA enables complete functional adaptation of the orofacial system and upper airway structures, leading to improved patient comfort and better therapeutic outcome. The primary objective of the study is to determine the effectiveness of OSA therapy in patients with skeletal Class I (eugnathic jaw relationship) using a DYNAMIC PROPULSION ORAL APPLIANCE (DPOA) with a mechanism that provides controlled, gentle, gradual and automatic mandible movement in propulsion during sleep.

Interventions

DEVICEdynamic propulsion oral appliance treatment (DPOA)

application of dynamic propulsion oral appliance for the treatment of obstructive sleep apnea during the sleeping phase

DEVICEelastic mandibular advancement appliance treatment

treatment of obstructive sleep apnea with elastic mandibular advancement appliance during the sleeping phase

Sponsors

University of Belgrade
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age between 20 and 65 years * clinically confirmed diagnosis of mild or moderate obstructive sleep apnea (Apnea hypopnea index 15-30 episodes/hour) * sufficient number of periodontally healthy teeth to support the oral appliance * written informed consent of conformance with the study protocol

Exclusion criteria

* age bellow 20 and over 65 years * patients not able or not willing to follow the study protocol * patients with severe OSA (Apnea hypopnea index \> 30 episodes/hour) and/or some other breathing disturbances * patients with psychiatric, neurological or psychosomatic disorders * patients with Body Mass Index \> 29kg/sqm * pregnancy * presence of the anatomical obstruction in the airways * severe periodontal disease (III and IV grade) * pathological changes in the structures of TMJ, muscles or ligaments * mandibular protrusion less than 3mm * orthodontic anomalies, malocclusions, II and III skeletal class, and orthodontic appliances

Design outcomes

Primary

MeasureTime frameDescription
nasal airflowprior to treatment and 3 months after the treatment initiationmeasured by respiratory poligraphy (ml/min)
oxygen saturationprior to treatment and 3 months after start of the treatmentmeasured by respiratory poligraphy in the range 0-100%
heart rateprior to treatment and 3 months after treatment initiationmeasured by respiratory poligraphy in the range 30 - 250 bpm
nasal air pressureprior to the treatment and 3 months after the treatment initiationmeasured by respiratory poligraphy
toracal and abdominal strainprior to the treatment and 3 months after treatment initiationmeasured by respiratory poligraphy
audio recording of breathing and snoringprior to the treatment and 3 months after treatment initiationmeasured by respiratory poligraphy
body posture and activityprior to the treatment and 3 months after the treatment initiationmeasured by pulmonary poligraphy

Secondary

MeasureTime frameDescription
sleepness monitoringprior to the treatment and 3 months after the treatment initiationmeasured by Epworth Sleepness Scale (a self-administered, 8-question survey measuring daytime sleepiness by rating the likelihood of dozing in common, sedentary situations; scores range from 0-24, with higher numbers indicating excessive daytime sleepiness)
snoring and breathing disruption during the sleepprior to the treatment and 3 months after the treatment initiationmeasured by Berlin Questionnaire (snoring intensity, frequency, and witnessed apnea - questions Nr. 1 to Nr. 5, a positive score indicates a high risk of OSA
daily sleepiness monitoringprior to the treatment and 3 months after the treatment initiationmeasured by Berlin Questionnaire (daytime sleepiness, fatigue, or nodding off while driving - questions Nr. 6 to Nr. 9, positive score indicates high risk of OSA)
presence of hypertension and/or obesityprior to the treatment and 3 months after the treatment initiationmeasured by Berlin Questionnaire (History of high blood pressure (\>140/90) or Body Mass Index (BMI) \>30 kg/m2 - question 10)

Countries

Serbia

Contacts

CONTACTVojkan Lazić, DDS PhD, full professor
stomfak@afrodita.rcub.bg.ac.rs+381112685288
PRINCIPAL_INVESTIGATORAleksandra Čairović, DDS PhD

University of Belgrade School of Dental Medicine

PRINCIPAL_INVESTIGATORLuka Župac, DDS, PhD student

University of Belgrade School of dental Medicine

PRINCIPAL_INVESTIGATORMarija S Milic, DDS PhD

University of Belgrade School of Dental Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026